STRETCHING IN ANKYLOSING SPONDYLITIS

Status Completed

Clinical Trial Summary

To evaluate the effects of stretching exercise in patients with ankylosing spondylitis at quality of life, functional capacity in patients with BASDAI lower than 4.Evaluate 40 patients with the diagnose of ankylosing spondylitis according to the criteria of the American College of rheumatology provenient from FMUSP at Clinical Hospital of São Paulo.

Clinical Trial Description

The evaluation complies BASFI, BASDAI, BASMI,BAS-G, ASQOL, SF 12,MASES, finger to floor distance, intermaleolar distance, lateral rotation of head, lateral flexion of the head, stiffness VAS, chest expasibility, Pavelka evaluation. All patients are allocatted randomly into 2 groups. One control with no exercise or group 1 with stretching exercise ( 30 minutes). ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01690273
Study type	Interventional
Source	University of Sao Paulo
Contact
Status	Completed
Phase	N/A
Start date	July 2012
Completion date	June 2013

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02685904` - A Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis	Phase 3
Completed	`NCT02186873` - A Study of Golimumab in Participants With Active Ankylosing Spondylitis	Phase 3
Completed	`NCT01668004` - The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012)	Phase 4
Completed	`NCT05051943` - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Completed	`NCT01934933` - Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis	Phase 4
Not yet recruiting	`NCT04875299` - Optimal Adalimumab Plasma Concentrations in Ankylosing Spondylitis Patients
Completed	`NCT02758782` - NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis	Phase 4
Completed	`NCT02763111` - Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing Spondylitis	Phase 2
Active, not recruiting	`NCT02687620` - Does Immunogenicity Have an Influence on the Efficacy of Anti-TNF Therapy in Patients With AS: An Inception Cohort Study
Completed	`NCT02154425` - A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers	Phase 1
Completed	`NCT01750528` - Prevalence and Progression of Periodontitis in Ankylosing Spondylitis	N/A
Completed	`NCT01463189` - Web-based Support to Manage Arthritis Pain	Phase 2
Completed	`NCT01091675` - Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs	Phase 3
Completed	`NCT00844805` - Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)	Phase 3
Recruiting	`NCT00747578` - Health-Related Quality of Life and Disease-Related Costs: Comparison Between Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus in Taiwan	N/A
Completed	`NCT00715091` - Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on RAdiographic Damage in Ankylosing Spondylitis	Phase 4
Completed	`NCT01083693` - Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs	N/A
Not yet recruiting	`NCT00517101` - Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy	N/A
Completed	`NCT00367211` - Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.	Phase 3
Completed	`NCT00133315` - TNFalfa Blocking Treatment of Spondylarthropathies	Phase 4